WAKE FOREST UNIVERSITY HEALTH SCIENCES

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain Tumors

Phase 3

Completed

Conditions: Brain Tumors
Metastatic Disease

Interventions: Drug: Placebo
Drug: donepezil hydrochloride

First Posted Date: 2006-08-29

Last Posted Date: 2021-10-20

Lead Sponsor: Wake Forest University Health Sciences

Target Recruit Count: 198

Registration Number: NCT00369785

Locations: 🇺🇸
Gundersen Lutheran Center for Cancer and Blood, La Crosse, Wisconsin, United States
🇺🇸
United States Air Force Medical Center - Wright-Patterson, Wright-Patterson Air Force Base, Ohio, United States
🇺🇸
Cancer Center of Kansas, PA - Wichita, Wichita, Kansas, United States

and more 13 locations

Breath Analysis Technique to Diagnose Pulmonary Embolism

Phase 2

Completed

Conditions: Pulmonary Embolism

Interventions: Device: BreathScreen PE

First Posted Date: 2006-08-29

Last Posted Date: 2022-04-21

Lead Sponsor: Wake Forest University Health Sciences

Target Recruit Count: 475

Registration Number: NCT00368836

Locations: 🇺🇸
Carolinas Medical Center, Charlotte, North Carolina, United States

Soy Protein/Effexor Hormone Therapy for Prostate Cancer

Phase 3

Terminated

Conditions: Hot Flashes
Prostate Cancer

Interventions: Dietary Supplement: Placebo Powder
Drug: Venlafaxine
Dietary Supplement: oral soy protein/isoflavones powder
Drug: Placebo Pill

First Posted Date: 2006-07-20

Last Posted Date: 2021-09-28

Lead Sponsor: Wake Forest University Health Sciences

Target Recruit Count: 120

Registration Number: NCT00354432

Locations: 🇺🇸
CCOP - Heartland Research Consortium, Saint Louis, Missouri, United States
🇺🇸
MBCCOP - JHS Hospital of Cook County, Chicago, Illinois, United States
🇺🇸
CCOP - Northern Indiana CR Consortium, South Bend, Indiana, United States

and more 17 locations

Docetaxel and Capecitabine in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cavity Cancer

Phase 2

Terminated

Conditions: Fallopian Tube Cancer
Ovarian Cancer
Peritoneal Cavity Cancer

Interventions: Drug: capecitabine
Drug: docetaxel

First Posted Date: 2006-07-20

Last Posted Date: 2017-08-30

Lead Sponsor: Wake Forest University Health Sciences

Target Recruit Count: 2

Registration Number: NCT00354601

Locations: 🇺🇸
Wake Forest University Comprehensive Cancer Center, Winston-Salem, North Carolina, United States

Clonidine Versus Adenosine to Treat Neuropathic Pain

Phase 2

Completed

Conditions: Pain

Interventions: Drug: adenosine
Drug: placebo
Drug: clonidine

First Posted Date: 2006-07-10

Last Posted Date: 2018-09-10

Lead Sponsor: Wake Forest University Health Sciences

Target Recruit Count: 24

Registration Number: NCT00349921

Locations: 🇺🇸
The Center for Clinical Research, 145 Kimel Park Drive, Winston-Salem, North Carolina, United States
🇺🇸
Wake Forest University School of Medicine, Medical Center Boulevard, Winston-Salem, North Carolina, United States

Clonidine-induced Spinal Acetylcholine Release: Normal Volunteers vs. Neuropathic Pain

Phase 2

Completed

Conditions: Pain

Interventions: Drug: clonidine

First Posted Date: 2006-07-10

Last Posted Date: 2018-09-10

Lead Sponsor: Wake Forest University Health Sciences

Target Recruit Count: 43

Registration Number: NCT00350532

Locations: 🇺🇸
The Center for Clinical Research, 145 Kimel Park Drive, Winston-Salem, North Carolina, United States
🇺🇸
Wake Forest University School of Medicine, Medical Center Boulevard, Winston-Salem, North Carolina, United States

Intrathecal Ketorolac in Patients With Intrathecal Morphine Dose Escalation

Phase 2

Withdrawn

Conditions: Pain

First Posted Date: 2006-07-07

Last Posted Date: 2017-11-06

Lead Sponsor: Wake Forest University Health Sciences

Registration Number: NCT00349401

Soy Supplements in Treating Patients Undergoing Surgery for Localized Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Dietary Supplement: soy isoflavones
Other: placebo
Dietary Supplement: soy protein isolate

First Posted Date: 2006-06-29

Last Posted Date: 2018-08-10

Lead Sponsor: Wake Forest University Health Sciences

Target Recruit Count: 62

Registration Number: NCT00345813

Locations: 🇺🇸
Wake Forest University Comprehensive Cancer Center, Winston-Salem, North Carolina, United States

Understanding the Genetic and Hereditary Basis of Atherosclerosis

Completed

Conditions: Cardiovascular Diseases
Atherosclerosis

First Posted Date: 2006-06-26

Last Posted Date: 2017-11-08

Lead Sponsor: Wake Forest University Health Sciences

Target Recruit Count: 2763

Registration Number: NCT00344292

Locations: 🇺🇸
The University of Texas, Houston, Texas, United States
🇺🇸
Cedars-Sinai Health System, Los Angeles, California, United States
🇺🇸
Louisiana State University, New Orleans, Louisiana, United States

and more 1 locations

Soy-Based Meal Replacement in Helping Women With Stage I, Stage II, or Stage III Breast Cancer in Complete Remission Lose Weight

Not Applicable

Completed

Conditions: Obesity
Breast Cancer

First Posted Date: 2006-06-23

Last Posted Date: 2017-01-19

Lead Sponsor: Wake Forest University Health Sciences

Target Recruit Count: 25

Registration Number: NCT00343434

Locations: 🇺🇸
Wake Forest University Comprehensive Cancer Center, Winston-Salem, North Carolina, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy